Events

May 5, 2025

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

The partnership combines VERAXA's proprietary ADC technology with OmniAb's antibody discovery technology for novel therapies targeting solid tumors.

April 23, 2025

‍Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies.

December 12, 2024

VERAXA Biotech and Navigo Proteins Initiate Research Collaboration to Establish Pre-Targeting Strategies for Novel Affilin Radio Conjugates

The agreement brings together Navigo Protein’s Affilin® platform with VERAXA’s proprietary click chemistry platform and conjugation expertise